GI
SMMT icon

GAMMA Investing’s Summit Therapeutics SMMT Stock Holding History

GAMMA Investing’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$45.6K Buy
2,697
+1,029
+62% +$15.4K ﹤0.01% 2427
2026
Q2 		$24.3K Buy
1,668
+29
+2% +$514 ﹤0.01% 2737
2026
Q1 		$31.1K Buy
1,639
+834
+104% +$13.5K ﹤0.01% 2484
2025
Q4 		$14.1K Sell
805
-173
-18% -$3.25K ﹤0.01% 2805
2025
Q3 		$20.2K Buy
978
+67
+7% +$1.63K ﹤0.01% 2508
2025
Q2 		$19.4K Buy
911
+86
+10% +$1.96K ﹤0.01% 2476
2025
Q1 		$15.9K Buy
825
+242
+42% +$4.86K ﹤0.01% 2516
2024
Q4 		$10.4K Buy
583
+106
+22% +$2.06K ﹤0.01% 2594
2024
Q3 		$10.4K Buy
477
+449
+1,604% +$6.28K ﹤0.01% 2438
2024
Q2 		$218 Sell
28
-2
-7% -$11 ﹤0.01% 3320
2024
Q1 		$124 Buy
+30
New +$119 ﹤0.01% 3276

Other funds holding SMMT

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
MHR
Matthew Hamilton Rosenberg $558M AUM 12.28% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM

GAMMA Investing's SMMT Position: Q3 2026 in Review

GAMMA Investing increased its Summit Therapeutics (SMMT) stake by 62% in Q3 2026, buying an estimated $15.4K and bringing the position to 2,697 shares worth $45.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

GAMMA Investing first reported a position in SMMT in Q1 2024 and has held it in 11 quarters since. 10 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • GAMMA Investing held 2,697 shares of Summit Therapeutics worth $45.6K as of Q3 2026.
  • GAMMA Investing bought 1,029 Summit Therapeutics shares in Q3 2026, an estimated $15.4K.
  • Summit Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2427 holding.
  • GAMMA Investing first reported a position in Summit Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • 10 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.